MedDataX Logo

Measles Vaccine in HCW

NCT ID: NCT04357028

Last Updated: 2020-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-13

Study Completion Date

2021-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

MMR vaccine, Respiratory failure,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MMR vaccine

0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm

Group Type EXPERIMENTAL

Measles-Mumps-Rubella Vaccine

Intervention Type DRUG

Measles mumps Rubella vaccine is a weak attenuated life vaccine

Control

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Group Type PLACEBO_COMPARATOR

Placebos

Intervention Type DRUG

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measles-Mumps-Rubella Vaccine

Measles mumps Rubella vaccine is a weak attenuated life vaccine

Intervention Type DRUG

Placebos

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-50 years old
* Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion Criteria

* acute severe illness
* recent receipt of a blood product
* history of thrombocytopenia
* Pregnant females
* any chronic medical condition
* Any participant receiving any immune suppressive medication
* Immunocompromised staff
* Participants who have egg allergy
* Participants who care for immune compromised hosts
* Participants who test positive for COVID-19 serology prior to randomization
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Mukhtar

professor of anesthesia and intensive care

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo University Hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-30-2020

Identifier Type: -

Identifier Source: org_study_id